Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Outcome Trial of Ivabradine in Chronic Heart Failure: The Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT)
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: Elevated heart rate is a significant marker for mortality and morbidity in cardiovascular disease including heart failure. Despite background treatment with a beta-blocker, many patients with heart failure and low ejection fraction maintain a heart rate above 70 b.p.m. Ivabradine reduces heart rate directly through inhibition of the If ionic current. Methods: SHIFT is a randomized, double-blind study designed to compare ivabradine with placebo on outcomes in patients with symptomatic chronic heart failure (NYHA class II–IV), left-ventricular ejection fraction ≤35%, and a prior hospitalization for worsening heart failure within the previous 12 months. Randomized treatment is given on top of guidelines-based therapy for chronic heart failure, including a beta-blocker at optimized dose. Resting heart rate at baseline must be ≥70 b.p.m. The primary endpoint is the composite of the time to first event of cardiovascular death or hospitalization for worsening heart failure. Secondary endpoints include all-cause, cardiovascular and heart failure mortality, and hospitalization. The randomized treatment period lasts approximately 12–48 months. The study will include approximately 6500 patients and will continue until ≥1600 primary endpoints have occurred. The first patient was randomized in October 2006, and the study is expected to end in 2010. Conclusion: The SHIFT study will assess if a heart rate reduction by direct sinus node inhibition can reduce cardiovascular outcomes in patients with chronic heart failure and left-ventricular systolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: the current state of play
Brooks, R. (1996) · Health Policy · doi:10.1016/0168-8510(96)00822-6 · Cited by 5,815
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099 · cited 1×
“at 12 months.(33) The drug had no effect on the primary composite outcome of cardiovascular death, admission to hospital for acute myocardial infarction, or admission to hospital for new-onset or worsening heart failure.”
BackgroundSelf-citationResting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789 · cited 1×
“m.(8) Treatment with beta-blockers has improved morbidity and mortality in patients with chronic heart failure.”
BackgroundSelf-citationβ-Blockers in Chronic Heart Failure
Gheorghiade, M., Colucci, W. S., & Swedberg, K. (2003) · Circulation · doi:10.1161/01.cir.0000065187.80707.18 · Cited by 167
Self-citation
Cited by
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationBöhm, M., Swedberg, K., Komajda, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,099
Self-citationTardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Self-citationSwedberg, K., Komajda, M., Böhm, M., Borer, J., Robertson, M., Tavazzi, L., & Ford, I. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.020 · Cited by 262
Self-citationBöhm, M., Borer, J., Ford, I., Gonzalez-Juanatey, J. R., Komajda, M., Lopez-Sendon, J., Reil, J.-C., Swedberg, K., & Tavazzi, L. (2013) · Clinical Research in Cardiology · doi:10.1007/s00392-012-0467-8 · Cited by 248
Self-citation
Metadata
- Authors
- Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., & Tavazzi, L.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-18
- Volume
- 12
- Issue
- 1
- Pages
- 75-81
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2058708816
- Cited by
- 97
- References
- 7
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Outcome Trial of Ivabradine in Chronic Heart Failure: The Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT). https://app.cochat.ai/papers/10.1093/eurjhf/hfp154
- The paper
- Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., & Tavazzi, L. (2010). Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Outcome Trial of Ivabradine in Chronic Heart Failure: The Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT). European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfp154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.